Category: Stock Market

Mesoblast Ltd (ASX: MSB) shares are edging lower despite the biotech company delivering another upbeat commercial update today.

In early afternoon trade, the Mesoblast share price is down 0.47% to $2.12. By comparison, the S&P/ASX 200 Index (ASX: XJO) is hovering 1.5% higher to 8,696 points.

The weaker move for Mesoblast suggests the market may now be waiting for the next bigger catalyst after the stock’s strong recovery over the past year.

Here’s what the market is weighing up.

Ryoncil keeps building momentum

According to today’s update, Mesoblast’s flagship cell therapy Ryoncil generated net sales of US$30.3 million during the March quarter.

Management said this completed the product’s first full year launch cycle. Growth in February and March more than offset the usual seasonal weakness seen in January.

That puts cumulative net revenue since launch close to US$100 million, a major commercial milestone for a company that spent years working toward US commercialisation.

Ryoncil remains Mesoblast’s first FDA-approved product and is currently approved in the United States for steroid-refractory acute graft-versus-host disease in children.

The company said the product’s profitability is helping fund its broader late-stage pipeline. This includes label expansion studies and other inflammatory disease programs.

Why the market may still be cautious

Even with the positive sales result, the share price reaction has remained lowkey.

Part of that likely reflects how much optimism had already been priced in earlier this year when Mesoblast shares hit a 52-week high above $3.30 in January.

At $2.12, the stock is now trading well below that level, even as operating progress continues.

The company’s market capitalisation still sits near $2.75 billion, showing investors still see considerable value in the rest of its pipeline.

The softer move today may also reflect the fact that this release focused on quarterly sales progress rather than upgraded guidance, regulatory milestones, or new clinical data.

After such a strong run in recent quarters, the market may now be waiting for the next major clinical or commercial update before bidding the shares higher again.

What to watch next

The next major watchpoint is whether Mesoblast can keep quarterly sales growth building toward its previously guided FY2026 Ryoncil net revenue range of US$110 million to US$120 million.

If sales momentum continues, attention is likely to shift toward margin improvement, cash generation, and progress across its late-stage pipeline.

Despite today’s positive update, Mesoblast shares are down roughly 21% since the start of the year.

The post Mesoblast shares are back in the red on Tuesday. Here’s why appeared first on The Motley Fool Australia.

More reading

• ASX 200 surging as investors look beyond Iran war
• Mesoblast shares: Ryoncil® underpins strong earnings growth
• Capricorn Metals delivers solid Q3 FY26 gold production and growth update
• Summerset Group Q1 2026 sales rise on robust demand
• Ramelius Resources confirms guidance, strong March quarter gold output

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are surging on Tuesday, rising by 2.6% or 224.5 points to an intraday peak of 8,804 points.

All 11 ASX 200 market sectors are higher today, with tech shares in the lead, up 6.2%, followed by materials and financials, both up 2.8%.

As we’ve previously reported, ASX investors appear keen to buy the dip after a 7.8% fall for ASX 200 shares in March.

Trading in April has been volatile, but overall, ASX 200 shares are already 3.5% higher this month.

However, investors are buying ASX 200 shares amid continuing uncertainty as to how the Iran war will play out.

Regardless of when the war ends, the global energy shock will reverberate for months, potentially pushing up inflation and interest rates.

But today, investors appear to be looking through those near-term risks.

Initial panic over the conflict and oil shock appears to be subsiding, with investors reverting to their traditional forward-looking nature.

When investors aren’t panicking about daily news, they tend to trade on what they expect will happen over the next six to 12 months.

Last week, James Gerrish from Shaw and Partners said the “war fear” in the market was fading, although “we’re not out of the woods yet”.

Gerrish noted that the ASX 200’s steep fall in March was “potentially affording an opportunity to buy high-performing stocks at a cheaper entry”.

Are investors buying the dip?

In the surging tech sector today, WiseTech Global Ltd (ASX: WTC) shares are up 5.8% to $40.06.

The Xero Ltd (ASX: XRO) share price is up 4.4% to $77.31.

TechnologyOne Ltd (ASX: TNE) shares are up 4.7% to $28.17 and Life360 Inc (ASX: 360) is up 5% to $19.64.

Nextdc Ltd (ASX: NXT) shares are 13.3% higher at $12.76 after the company announced a $1 billion hybrid securities offer.

Among the miners, the BHP Group Ltd (ASX: BHP) share price is up 3.3% to $52.97.

Rio Tinto Ltd (ASX: RIO) shares are up 2.6% to $165.88 and Fortescue Ltd (ASX: FMG) is 2.3% higher at $20.72.

The largest ASX 200 lithium mining share, PLS Group Ltd (ASX: PLS), is up 2.9% to $5.24.

The market’s largest ASX 200 gold share, Northern Star Resources Ltd (ASX: NST) is 3.4% higher at $22.65.

Among the financials, the Commonwealth Bank of Australia (ASX: CBA) share price is $178.08, up 3.1%.

National Australia Bank Ltd (ASX: NAB) shares are up 3% to $43.04.

Westpac Banking Corp (ASX: WBC) shares are $40.88, up 2.6%, and ANZ Group Holdings Ltd (ASX: ANZ) shares are $37.60, up 2.7%.

Zip Co Ltd (ASX: ZIP) shares are flying on Tuesday, up 8.6% to $1.71.

In energy, Woodside Energy Group Ltd (ASX: WDS) shares are $35.24, up 0.9%, while Santos Ltd (ASX: STO) is $8.07, down 0.2%.

Oil prices continue to trade close to four-year highs.

Brent crude is US$110.40 a barrel, up 0.5%, and WTI crude is US$113.50 per barrel, up 0.9% on Tuesday.

What’s the latest in the Middle East?

The US says it is continuing to negotiate with Iran amid a renewed threat from the President that the US will bomb Iran’s power plants.

Over the weekend, US President Donald Trump said he would target power plants and bridges if Iran did not re-open the Strait of Hormuz.

In an expletive-laden post on Truth Social, President Trump said:

Tuesday will be Power Plant Day, and Bridge Day, all wrapped up in one, in Iran.

There will be nothing like it!!!

Open the Fuckin’ Strait, you crazy bastards, or you’ll be living in Hell – JUST WATCH! Praise be to Allah.

Technically, the strait is not closed. However, no shipping company is willing to sail through it given the risk of Iran attacks.

Iran reportedly rejected a ceasefire proposal over the weekend.

Iran also vowed to respond to any US strikes on civilian infrastructure by attacking the energy assets of Gulf neighbours.

The post ASX 200 surging as investors look beyond Iran war appeared first on The Motley Fool Australia.

More reading

• Mesoblast shares are back in the red on Tuesday. Here’s why
• Why is everyone talking about Telix, Bank of Queensland and NextDC shares today?
• Here’s the dividend forecast out to 2028 for NAB shares
• Up 59% in a year, should you still buy BHP shares today?
• Fortescue shares: 3 reasons to buy and 3 reasons to sell

Motley Fool contributor Bronwyn Allen has positions in BHP Group and Zip Co. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Technology One, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended Life360, WiseTech Global, and Xero. The Motley Fool Australia has recommended BHP Group and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Knowing which ASX shares to avoid can be just as important as knowing which ones to buy.

With that in mind, let’s take a look at three shares that analysts are tipping as sells this week, courtesy of The Bull.

Here’s what you need to know about them:

Centuria Industrial REIT (ASX: CIP)

The team at Investor Pulse is recommending this industrial property company’s shares as a sell this week.

It has concerns about industrial rent growth and the impact of rising interest rates. It said:

As the largest pure play industrial fund in Australia with a portfolio of 85 high quality assets, the trust has delivered solid growth, including a 40 megawatt data centre expansion. Yet the market is increasingly wary about industrial rent growth amid a cooling economy. A potentially looming supply issue may peak in mid calendar year 2026, which could challenge historically low vacancy rates in urban markets.

Rising interest rates on debt is another concern for a company with a $3.9 billion portfolio. Although the portfolio maintains an occupancy rate of 95.7 per cent and a weighted average lease expiry of 7.1 years, broader economic headwinds remain.

DigiCo Infrastructure REIT (ASX: DGT)

Over at Morgans, its analysts have named data centre operator DigiCo Infrastructure as a sell.

Although the broker acknowledges that data centre demand is positive, it is waiting for management to deliver before becoming positive. This is especially the case given its poor first-half performance. Morgans said:

DGT is a data centre real estate investment trust. This developer operates across Australia and North America. The REIT requires significant capital expenditure to expand in an already competitive environment. The company’s first half result in fiscal year 2026 and its profit forecasts for the full year fell short of investor expectations.

While the outlook in the data centre space has incrementally improved, management will need to deliver before there is meaningful conviction in the business. Shares in DGT were priced at $5 in the initial public offering prior to listing on the ASX on December 13, 2024. The shares were trading at $1.89 on April 2, 2026.

Endeavour Group Ltd (ASX: EDV)

Investor Pulse is also recommending investors sell this drinks giant’s shares.

After a tough first half, it is concerned that there could still be worse to come. This could mean analysts are forced to lower their earnings estimates in the coming months. It said:

Endeavour operates liquor outlets, hotels and gaming facilities. In our view, key concerns emerged in its first half result in fiscal year 2026. Underlying group earnings before interest and tax of $563 million fell 5.4 per cent despite a 0.9 per cent increase in group sales to $6.7 billion.

While the hotels segment generated a 4.4 per cent increase in sales, the retail division, comprising Dan Murphy’s and BWS, posted a 11.6 per cent decline in underlying EBIT. Statutory net profit after tax fell 17.1 per cent to $247 million, impacted by $45 million in significant items. Downward revisions in consensus earnings per share suggest the bottom may not have been reached at this point.

The post Experts name 3 ASX shares to sell appeared first on The Motley Fool Australia.

More reading

• 3 top ASX dividend share buys for passive income in April
• 3 ASX income stocks trading at attractive prices
• 4 ASX shares at 52-week lows: Buy, hold, or sell?
• Buy, hold, sell: Endeavour, Magellan, and Rio Tinto shares
• 1 ASX dividend stock down 18% I’d buy right now!

Motley Fool contributor James Mickleboro has positions in Endeavour Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Bank of Queensland Ltd (ASX: BOQ), Telix Pharmaceuticals Ltd (ASX: TLX), and NextDC Ltd (ASX: NXT) shares are grabbing headlines today.

In late morning trade on Tuesday, all three blue-chip stocks are racing ahead of the 2.6% intraday gains posted by the S&P/ASX 200 Index (ASX: XJO).

Here’s what’s happening.

NextDC shares leap on $1 billion funding news

Turning to NextDC first, shares in the ASX 200 data centre operator and developer are up 13.6% today, trading for $12.79 apiece.

Investors are sending NextDC shares surging after the company announced it was raising $1 billion in new funds via the issue of new hybrid securities.

The hybrid securities launch is backed by Canadian investment group La Caisse, which inked a binding $1 billion commitment to make up for any potential shortfall.

The securities carry a 100-year maturity.

The new funds will support NextDC’s plans to develop new data centres and expand capacity.

Commenting on the fund-raising initiative that’s boosting NextDC shares today, CEO Craig Scroggie said:

The announcement of the Hybrid Securities Offer and the La Caisse commitment represent another step toward NextDC delivering on a material step-change in the scale of our business as we deliver on the company’s contracted forward order book across the period to FY29 and make further investments across the portfolio of new projects.

Which brings us to…

Telix shares surge on revenue growth

Telix shares are also catching plenty of investor attention today.

Shares in the ASX 200 diagnostic and therapeutic product developer are up 6.3% today, trading for $13.77 each.

This follows the release of Telix’s March quarterly update.

Among the highlights, the company reported an 11% quarter-on-quarter increase in unaudited revenue to US$230 million. And management reaffirmed full-year FY 2026 revenue guidance in the range of US$950 million to US$970 million.

The March quarter saw the ASX healthcare share continue to advance its global studies across prostate, brain, and kidney cancer.

“We are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter,” Telix CEO Christian Behrenbruch said.

Bank of Queensland shares jump on strategic loan sale

Last, but not least, Bank of Queensland shares join Telix and NextDC shares in grabbing financial headlines and outperforming today.

Shares in the ASX 200 bank stock are up 5.3% at the time of writing, changing hands for $7.16 each.

Investors are bidding up Bank of Queensland shares after the company reported on its $3.7 billion equipment finance loan sale to investment management firm Challenger Ltd (ASX: CGF).

Why is this boosting the Bank of Queensland share price today?

As the Motley Fool reported this morning:

The capital partnership enables BOQ to accelerate its specialist banking transformation by shifting equipment finance exposures off balance sheet while growing capital-light revenues. The transition is designed to improve return on equity and support further business in the small and medium business sector.

The post Why is everyone talking about Telix, Bank of Queensland and NextDC shares today? appeared first on The Motley Fool Australia.

More reading

• ASX 200 surging as investors look beyond Iran war
• Why are Telix shares jumping 8% today?
• Why are NextDC shares surging higher?
• Bank of Queensland announces $3.7bn loan sale and capital partnership with Challenger
• NEXTDC announces $1 billion hybrid securities offer and La Caisse backing

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Challenger and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Weebit Nano Ltd (ASX: WBT) shares are back in the green on Tuesday, extending what has already been one of the ASX’s standout 12-month performances.

In morning trade, the Weebit Nano share price is up 2.54% to $3.64.

The latest gain adds to a remarkable rally that has seen the stock surge almost 150% over the past year, driven by growing confidence in its ReRAM memory technology and broader AI commercial opportunity.

With momentum still on its side, today’s rise suggests investors see further upside in the company’s next growth phase.

Retail investors get access after $80 million raise

Today’s update is the next stage of the recent capital raising, when Weebit Nano launched an $80 million institutional placement alongside an Israeli placement targeting up to $10 million.

The funds are intended to strengthen the balance sheet and support a faster push into next-generation memory and AI in-memory compute applications.

The newly opened SPP is targeting up to another $15 million, though management can accept additional demand or scale applications back.

The offer opened today and is scheduled to close on 29 April, with the new shares expected to be allotted on 6 May.

For existing shareholders, the SPP offers access at the same $4.05 price paid by institutions, without brokerage costs.

That said, with the stock trading at $3.64 this morning, the market is pricing the shares below the offer price. This could reduce short-term retail demand unless investors are looking further ahead to potential licensing growth.

Why investors are still interested

The bigger driver behind the strong 12-month share price performance is Weebit Nano’s licensing momentum.

The company’s ReRAM technology is being positioned as a lower-power replacement for embedded flash memory across AI, IoT, automotive, industrial automation, and edge computing devices.

Recent commercial wins, including its licensing agreement with Texas Instruments, have strengthened confidence that the technology is moving from early validation into broader commercial use.

With a market capitalisation of about $840 million, the stock remains one of the ASX tech sector’s biggest winners over the past 12 months.

Investors appear willing to look past the short-term dilution from the raise and stay focused on growth in AI memory markets.

Foolish takeaway

Tuesday’s gain suggests the market has responded well to Weebit Nano broadening its recent raise to include everyday retail shareholders.

The next focus will be SPP uptake and whether the fresh capital can help support additional foundry and semiconductor licensing deals in the year ahead.

The post This ASX tech stock is up 150% in a year. Here’s why it’s climbing again today appeared first on The Motley Fool Australia.

More reading

• Why DroneShield, Hub24, Syrah, and Weebit Nano shares are sinking today
• Why are Weebit Nano shares crashing 15% today?
• This ASX tech stock is frozen today. Here’s what’s going on
• 4 ASX tech shares tipped to jump up to 140% higher

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX bank share space could be an appealing place to invest during the rising interest rate environment. Owning National Australia Bank Ltd (ASX: NAB) shares is one of the options to consider for dividends.

The bank may benefit from the Reserve Bank of Australia (RBA) increasing the cash rate because NAB can lend out transaction account balances for a higher return (but the cost is minimal and doesn’t change, unlike a savings account balance, during rate hikes).

But, there is a danger of higher loan arrears and bad debts due to rate rises, which may be a headwind for NAB’s profit. Let’s have a look at what could happen with the dividend in the coming years.

FY26

The bank recently reported its FY26 first quarter which included some strong positives.

It said it generated $2.02 billion of cash earnings, representing a 16% increase year-over-year. The bank said that underlying net profit grew by 12% year-over-year.

The bank said it was executing across key priorities including growing business banking, driving deposit growth and strengthening its own-channel (proprietary) home lending.

Australian business lending rose 2%, with market share gains in small and medium enterprises (SMEs) and total business lending.

Its Australian home lending grew by 1.1x the speed of the overall lending system, implying that it grew market share.

NAB also noted that its deposit balances in business and private banking and personal banking, increased 3%, including 6% growth in transaction accounts excluding offsets.

The ASX bank share is also targeting productivity savings of more than $450 million for FY26 and it’s also aiming for FY26 operating expense growth to be less than FY25 growth of 4.6%.

In terms of the dividend for owners of NAB shares, the projection on CMC Invest suggests that the ASX bank share could pay an annual payout of $1.705 in FY26. At the time of writing, that’s a dividend yield of 4.1%, or 5.8% including franking credits.

FY27

Time will tell what happens with the Middle East, fuel prices, inflation and interest rates, but I wouldn’t be surprised if we’re still living with the effects of it in the 2027 financial year.

Currently, analysts are projecting an increase in the NAB dividend in the 2027 financial year. In this period of uncertainty. If I were a shareholder, I’d be happy with any sort of dividend growth during economic challenges.

The projection on CMC Invest suggests that NAB could hike its annual dividend per share by 1.5% to $1.73.

FY28

The final year of this series of projections is the 2028 financial year, which could see another year of growth for the dividend.

Currently, the forecast on CMC Invest suggests the annual payout could grow another 1.7% year-over-year to $1.76 per share.

That’s certainly not the strongest growth rate around for dividend rises, but it’s a lot better than nothing and would ensure a pleasing ongoing dividend yield for investors.

The post Here’s the dividend forecast out to 2028 for NAB shares appeared first on The Motley Fool Australia.

More reading

• What happened with ASX 200 bank stocks like CBA and Westpac in March?
• How many NAB shares do I need to buy for $10,000 a year in passive income?
• Which ASX bank has the biggest dividend yield?
• Why NAB shares are slipping today despite a major business reset
• Buy, hold, sell: NAB, Pro Medicus, and Telstra shares

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are looking for exposure to the mining sector this week, then it could be worth hearing what the team at Fairmont Equities is recommending, courtesy of The Bull.

Let’s see what the equities firm is recommending to Aussie investors:

Betashares Global Uranium ETF (ASX: URNM)

The first ASX mining share that Fairmont Equities is tipping as a buy this week is actually an exchange traded fund (ETF).

The Betashares Global Uranium ETF provides investors with exposure to leading global stocks that are involved in the mining, exploration, development, and production of uranium, modern nuclear energy, or that hold physical uranium or uranium royalties.

Fairmont Equities thinks it would be a good option for investors given its positive view on the outlook for uranium. This is especially the case given a recent pullback in the ETF’s unit price.

Commenting on the ETF, the equities firm said:

I remain positive about the outlook for the uranium sector. URNM provides exposure to a portfolio of mining, exploration and development companies in the global uranium industry. URNM stock rose from $6.34 on April 3, 2025 to $15.24 on January 29, 2026.

The stock was trading at $12.31 on April 2, 2026. The recent dip provides investors with another buying opportunity. We expect demand for uranium to exceed supply in the years ahead, particularly as countries diversify their energy sources away from fossil fuels.

New Hope Corporation Ltd (ASX: NHC)

Another ASX mining share that could be a buy according to Fairmont Equities is coal miner New Hope.

The equities firm believes that demand for coal will remain strong, especially given the war in the Middle East. As a result, it thinks that New Hope is well-positioned to profit from this strong demand.

It also highlights that recent trading patterns are favourable, which it thinks points to significant upside potential.

Commenting on the mining share, Fairmont Equities said:

I have been bullish on this thermal coal producer for several months. I believe global demand for coal will remain elevated. The conflict in the Middle East is lifting demand for thermal coal, with countries, such as Japan, increasing coal-fired power generation to offset instability in gas markets. During the past few weeks, NHC shares broke out of a bullish technical pattern on strong volume, which implies significant upside from here.

The post 2 ASX mining shares to buy: Expert appeared first on The Motley Fool Australia.

More reading

• Why are shares in this uranium company surging today?
• 3 ASX ETFs to buy before the rally really takes off: expert
• These were the best-performing ASX 200 shares in March
• Why 4DMedical, New Hope, Santos, and St George Mining shares are dropping today
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BHP Group Ltd (ASX: BHP) shares are charging higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) mining giant closed on Thursday trading for $51.23. In morning trade on Tuesday, shares are changing hands for $52.92 apiece, up 3.3%.

That sees the share price up an impressive 53.1% over the past 12 months. And that’s not including the $1.958 in fully-franked dividends BHP paid out over the full year. If we add those back in, then the accumulated value of BHP shares has surged 58.8% since 7 April 2025.

Atop its own operational successes, the miner has enjoyed a resilient iron ore price. The industrial metal is trading at around US$107 per tonne today, up from US$99 per tonne a year ago.

Then there’s copper. At US$12,360 per tonne, the copper price is up 42% since this time last year.

Which brings us back to our headline question…

Are BHP shares still a good buy now?

For a deeper dive into this million-dollar question, we defer to three investing experts who ran their slide rules over the mining giant late last week (courtesy of The Bull).

“The commodities bull market has only just started, in my view,” said Fairmont Equities’ Michael Gable.

“As a global mining giant, BHP generally appeals to investors looking to increase exposure in the resources sector,” he added.

And Gable noted that BHP shares remain down 12% since closing at $59.25 on 2 March.

Summing up his hold recommendation on the ASX 200 mining stock he said:

BHP’s share price has retreated to a major support level since the start of the war in Iran. I’m confident the stock should bounce from these levels. BHP’s diversification makes it a safer bet for investors to ride the commodities bull market.

Morgans Financial’s Mitch Belichovski also has a current hold recommendation on BHP shares.

“BHP is a diversified mining company producing iron ore, copper, nickel, metallurgical coal and potash,” he said.

Belichovski added:

First half revenue in fiscal year 2026 grew 11% on the prior corresponding period and profit after tax was up 28%. The fully franked interim dividend of US73 cents a share was up 46% and ahead of consensus.

BHP’s fundamentals position it to play a recovery in China’s subdued growth. Capital expenditure cycles and copper growth provide a compelling reason to retain BHP as a core position in portfolios.

And another hold…

Also issuing a hold recommendation on BHP shares this week is Investor Pulse’s Mark Elzayed.

“The company remains a global resources powerhouse, increasingly focused on future-facing commodities, such as copper and potash,” he said. “The first half result in fiscal year 2026 highlights a robust performance across its portfolio.”

Elzayed sounded particularly bullish on BHP’s increasing copper production. He noted:

Iron ore continues to deliver strong cash flow, but copper has become the standout performer, contributing about 51% of total earnings. Copper production guidance has been upgraded to between 1.9 million tonnes and 2 million tonnes following record output at its Escondida operation and various South Australian assets.

Elzayed concluded:

Valuation metrics indicate that BHP was recently trading in line with historical enterprise value-to-earnings multiples, reflecting solid fundamentals and current commodity price expectations.

The post Up 59% in a year, should you still buy BHP shares today? appeared first on The Motley Fool Australia.

More reading

• Why I think BHP, CBA, and DroneShield shares are buys in April
• BHP shares just dropped — is this your chance to buy the dip?
• Buy, hold, sell: Aristocrat, BHP, and Woodside shares 
• Why now could be the time to buy these popular ASX ETFs
• How did these ASX blue-chip shares perform in March?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Fortescue Ltd (ASX: FMG) shares are trading in the green on Tuesday morning. At the time of writing, the shares are up 1.7% to $20.60 a piece.

The latest uptick means the shares have now climbed 8.3% over the past month, although they’re still down 7% for the year to date.

For the year, the shares are 43.7% higher. 

It’s been a volatile start to the year for Fortescue shares, so if you’re thinking of adding the stock to your portfolio, here are some things to consider. 

3 reasons to buy Fortescue shares

1. Attractive dividend yield

Because the miner is a low-cost producer, meaning it can remain profitable even when iron ore falls, it is able to pay a reliable dividend to investors. Fortescue is a popular high-yielding dividend-paying stock. Broker UBS predicts that Fortescue could pay an annual dividend per share of $1.22. At the time of writing, that translates into a grossed-up dividend yield of just over 5.92%, including franking credits.

2. Copper exposure

Fortescue is primarily an iron ore miner but it is actively expanding in the copper space. Not only will that give the miner more diversity and less reliance on the iron ore market, it could also give long-term operational upside. If its copper exposure keeps growing it would help support overall earnings.

3. Expansion and growth

Fortescue is continually investing in business expansion. Not only is the miner planning to grow its copper exposure, it is also focused on building significant renewable energy infrastructure, decarbonisation and expansion of its green energy projects, and developing and expanding its existing iron ore sites to improve production efficiency. These projects are positive for long-term profitability.

3 reasons to sell Fortescue shares

1. Heavily tied to iron ore prices

While Fortescue has a copper footprint, the miner primarily mines and exports iron ore. This means it is heavily reliant on the price of iron ore and is subject to any price fluctuations that the material might have. The price of iron ore is expected to soften through 2026 and then gradually decline through to 2030 as supply increases and Chinese steel demand tapers off.

2. The shares are overpriced

Fortescue’s share price is looking overvalued right now. While its current price-to-earnings (P/E) ratio of 11.54 looks attractive on the surface (the average P/E ratio within ASX metals and mining companies is anywhere between 12.5 and 25), it doesn’t take into account projected declines in earnings. UBS forecasts that the business will earn US$3.8 billion in net profit in FY26, but this is expected to drop to US$2.94 billion in FY27 off the back of lower iron ore prices.

3. Brokers rate the stock as a sell

Analysts are mostly bearish on Fortescue shares. TradingView data shows that nine out of 17 analysts have a hold rating on the stock, and another seven have a sell or strong sell rating. The average 12-month target price of $20.02 implies a potential 1.1% downside at the time of writing.

The post Fortescue shares: 3 reasons to buy and 3 reasons to sell appeared first on The Motley Fool Australia.

More reading

• Buying ASX 200 mining shares? Here’s how Rio Tinto, Fortescue and BHP stacked up in March
• ASX 200 mining shares ride a rollercoaster in March quarter
• 3 reasons why this could be a great time to buy Fortescue shares!
• ASX 200 mining shares rebound after March sell-off creates opportunities
• Is this ASX iron ore stock a better buy than Fortescue?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are on the move on Tuesday morning.

At the time of writing, the radiopharmaceuticals company’s shares are up 8.5% to $14.05.

Why are Telix shares rising today?

Investors have been buying Telix shares following the release of a quarterly update highlighting strong revenue growth and progress across its therapeutics pipeline.

According to the release, Telix reported unaudited group revenue of US$230 million for the first quarter of FY 2026, representing a 24% increase on the prior corresponding period and an 11% lift on the previous quarter.

Its Precision Medicine division was a key driver, delivering US$186 million in revenue, up 23% year on year and 16% quarter on quarter. This was supported by strong demand for its imaging products Illuccix and Gozellix.

Guidance reaffirmed

In addition to the strong quarterly performance, Telix has reaffirmed its full year revenue guidance.

The company continues to expect FY 2026 revenue in the range of US$950 million to US$970 million, reflecting confidence in ongoing growth across its commercial operations.

Management highlighted that this outlook is underpinned by continued expansion of its global footprint and increasing adoption of its products.

Pipeline progress continues

Telix also provided an update on its therapeutics pipeline, highlighting progress across multiple late-stage programs.

Notably, its TLX591-Tx prostate cancer therapy candidate met safety and dosimetry objectives in a Phase 3 study, with no new safety signals observed.

The company also continues to advance other clinical programs, including trials targeting kidney cancer and glioblastoma, as well as expanding patient recruitment across multiple regions.

In addition, Telix is progressing regulatory submissions, including the resubmission of its New Drug Application to the US Food and Drug Administration for its brain cancer imaging candidate TLX101-Px.

Management commentary

Telix’s managing director and CEO, Dr Christian Behrenbruch, was pleased with the quarter and appears positive on its outlook. He said:

Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model.

With our two-product PSMA imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter.

The post Why are Telix shares jumping 8% today? appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed
• These are the 10 most shorted ASX shares
• 3 ASX 200 healthcare shares to buy amid sector rout
• 3 reasons to buy this red-hot ASX healthcare stock today
• These were the best-performing ASX 200 shares in March

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.